Research Daily Summary: What Happened on October 23, 2026

Red blood cell microparticles amplify antitumor immunity in mice

Microparticles generated from ultraviolet-irradiated red blood cells acted as an adjuvant, a substance that strengthens an immune response, in laboratory tests and mouse tumor models.1 They favored T helper type 1 responses and increased tumor-specific cytotoxic T-cell activity.1

Dendritic cells took up the particles and carried haem through lysosomes to the nucleus.1 There, haem activated REV-ERBα, which reduced PPARγ activity and eased suppression of dendritic-cell maturation and antigen presentation.1

In vaccination experiments, the particles paired with tumor antigens increased cytotoxic T-cell activation and reduced tumor growth, with minimal toxicity reported.1 The findings come from preclinical work and do not establish whether the approach will work in people.1

GradientScreen tests drug combinations in pediatric leukemia

GradientScreen uses a microfluidic assay to test different drug ratios in pediatric acute lymphoblastic leukemia.2 Researchers used it to measure responses in patients who had not responded to standard treatment.2

The assay's combination-response measures correlated with minimal residual disease after treatment began and with later clinical outcomes.2

Also published

• Innovation Radar: Pancreatic cancer’s metabolic weak spots BioCentury
• Hydrogel for sustained and localized delivery of a regulatory T cell-inducing agent promotes bone regeneration Nature Biomedical Engineering
• Red blood cell-derived extracellular vesicles as a potent autologous adjuvant Nature Biomedical Engineering
• The human microbiome and chronic disease: ten strategic priorities for research and public health Nature Medicine